Enlivex (ENLV) Investor Overview: CEO Oren Hershkovitz on Enlivex’s Biotech + Crypto Strategy
Apr. 1, 2026
What makes Enlivex Therapeutics (Nasdaq: ENLV) a differentiated small-cap story?
In our investor overview, CEO Oren Hershkovitz explains Enlivex’s dual-engine strategy: advancing Allocetra™, a clinical-stage macrophage reprogramming cell therapy targeting osteoarthritis and age-related inflammatory conditions, while also building a digital asset treasury strategy centered on RAIN, a decentralized prediction markets protocol.
This model gives public market investors a unique way to access both late-stage clinical development and emerging decentralized forecasting infrastructure.
